How to buy Vir Biotechnology (VIR) shares in Australia
Learn how to easily invest in Vir Biotechnology shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Vir Biotechnology Inc is a biotechnology business with stocks listed in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$40.21 – an increase of 2.87% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Vir Biotechnology
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Vir Biotechnology. Find the share by name or ticker symbol: VIR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vir Biotechnology reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$43.52, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vir Biotechnology, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Vir Biotechnology. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Vir Biotechnology key stats
- Compare share trading platforms
- Is Vir Biotechnology stock a buy or sell?
- Vir Biotechnology performance over time
- Can I short Vir Biotechnology shares?
- Vir Biotechnology's financials
- How volatile are Vir Biotechnology shares?
- Does Vir Biotechnology pay a dividend?
- Other common questions
Vir Biotechnology stock price (NASDAQ:VIR)Use our graph to track the performance of VIR stocks over time.
Vir Biotechnology shares at a glance
|52-week range||US$25.31 - US$83.5|
|50-day moving average||US$43.7203|
|200-day moving average||US$43.609|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-2.327|
Where to buy Vir Biotechnology stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Vir Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Vir Biotechnology shares?Before you consider Vir Biotechnology, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Vir Biotechnology price performance over time
|1 week (2021-10-14)||-0.05%|
|1 month (2021-09-24)||-8.24%|
|3 months (2021-07-23)||9.00%|
|6 months (2021-04-23)||-17.79%|
|1 year (2020-10-23)||15.85%|
|2 years (2019-10-24)||181.19%|
Stocks similar to Vir Biotechnology
Vir Biotechnology financials
|Revenue TTM||US$182.7 million|
|Gross profit TTM||US$-196,511,000|
|Return on assets TTM||-18.69%|
|Return on equity TTM||-45.71%|
|Market capitalisation||US$5.3 billion|
TTM: trailing 12 months
Shorting Vir Biotechnology shares
There are currently 5.2 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 8.1% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR)
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 858538.7888707). Vir Biotechnology's SIR currently stands at 6.11. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 6110 shares are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 40 shares are currently held short) or 0.0754% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vir Biotechnology.
Find out more about how you can short Vir Biotechnology stock.
Vir Biotechnology share dividends
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Vir Biotechnology share price volatility
Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as US$25.31 up to US$83.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -1.314. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.
Vir Biotechnology overview
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology in the news
Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
Vir Biotechnology : to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
Frequently asked questions
More guides on Finder
Why is the AMP share price looking up today?
Shares in the wealth management giant have been largely stable in the last 6 months.
How to invest in the Judo Capital Holdings IPO
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
How to invest in the Alloggio Group IPO
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
How to invest in the Larvotto Resources IPO
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
How to invest in the Vulcan Steel IPO
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
How to invest in the Artrya IPO
Everything we know about the Artrya IPO, plus information on how to buy in.
How to invest in the 8 Au IPO
Everything we know about the 8 Au IPO, plus information on how to buy in.
How to invest in the Radiopharm Theranostics IPO
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
What has prompted the rebound in the Kogan share price?
The online retailer’s shares have lost more than half their value in the last 12 months.
How to invest in the GQG Partners IPO
Everything we know about the GQG Partners IPO, plus information on how to buy in.
Ask an Expert